Katherine Stueland Sells 1,657 Shares of GeneDx Holdings Corp. (NASDAQ:WGS) Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland sold 1,657 shares of GeneDx stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $78.48, for a total transaction of $130,041.36. Following the completion of the sale, the chief executive officer now directly owns 3,937 shares of the company’s stock, valued at approximately $308,975.76. This trade represents a 29.62 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Katherine Stueland also recently made the following trade(s):

• On Tuesday, January 7th, Katherine Stueland sold 51,420 shares of GeneDx stock. The stock was sold at an average price of $94.48, for a total transaction of $4,858,161.60.
• On Thursday, January 2nd, Katherine Stueland sold 18,006 shares of GeneDx stock. The stock was sold at an average price of $78.18, for a total transaction of $1,407,709.08.
• On Monday, December 16th, Katherine Stueland sold 10,501 shares of GeneDx stock. The stock was sold at an average price of $76.75, for a total transaction of $805,951.75.
• On Monday, December 9th, Katherine Stueland sold 3,661 shares of GeneDx stock. The stock was sold at an average price of $76.37, for a total transaction of $279,590.57.
• On Monday, November 18th, Katherine Stueland sold 22,307 shares of GeneDx stock. The stock was sold at an average price of $70.34, for a total transaction of $1,569,074.38.
• On Friday, November 15th, Katherine Stueland sold 23,108 shares of GeneDx stock. The shares were sold at an average price of $70.48, for a total transaction of $1,628,651.84.

GeneDx Price Performance

Shares of WGS traded down $3.01 during trading hours on Friday, reaching $74.85. 393,012 shares of the stock traded hands, compared to its average volume of 865,986. The company has a current ratio of 2.40, a quick ratio of 2.27 and a debt-to-equity ratio of 0.25. GeneDx Holdings Corp. has a 52-week low of $3.62 and a 52-week high of $98.87. The company’s 50-day moving average price is $78.37 and its two-hundred day moving average price is $57.69. The company has a market cap of $2.06 billion, a P/E ratio of -24.07 and a beta of 2.02.

GeneDx (NASDAQ:WGS) last released its earnings results on Tuesday, October 29th. The company reported $0.04 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.25. GeneDx had a negative net margin of 31.25% and a negative return on equity of 13.35%. The company had revenue of $76.90 million for the quarter, compared to analysts’ expectations of $64.98 million. During the same quarter in the previous year, the company earned ($0.82) EPS. GeneDx’s revenue for the quarter was up 44.3% on a year-over-year basis. On average, analysts anticipate that GeneDx Holdings Corp. will post -0.24 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on WGS shares. TD Cowen boosted their price objective on shares of GeneDx from $75.00 to $118.00 and gave the company a “buy” rating in a research report on Tuesday, January 7th. Wells Fargo & Company boosted their price objective on shares of GeneDx from $34.00 to $75.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 30th. The Goldman Sachs Group boosted their price objective on shares of GeneDx from $54.00 to $70.00 and gave the company a “neutral” rating in a research report on Wednesday, October 30th. Finally, Craig Hallum boosted their price objective on shares of GeneDx from $70.00 to $95.00 and gave the company a “buy” rating in a research report on Wednesday, October 30th. Three research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat.com, GeneDx has an average rating of “Moderate Buy” and a consensus price target of $70.67.

Institutional Trading of GeneDx

Several hedge funds have recently bought and sold shares of the stock. MCF Advisors LLC lifted its stake in GeneDx by 107.7% in the 4th quarter. MCF Advisors LLC now owns 351 shares of the company’s stock worth $27,000 after purchasing an additional 182 shares in the last quarter. Global Retirement Partners LLC purchased a new stake in GeneDx in the 4th quarter worth $28,000. Rhumbline Advisers lifted its stake in GeneDx by 5.5% in the 4th quarter. Rhumbline Advisers now owns 19,750 shares of the company’s stock worth $1,518,000 after purchasing an additional 1,021 shares in the last quarter. Principal Financial Group Inc. lifted its stake in GeneDx by 10.6% in the 4th quarter. Principal Financial Group Inc. now owns 15,751 shares of the company’s stock worth $1,211,000 after purchasing an additional 1,511 shares in the last quarter. Finally, Palumbo Wealth Management LLC lifted its stake in GeneDx by 22.8% in the 4th quarter. Palumbo Wealth Management LLC now owns 8,303 shares of the company’s stock worth $638,000 after purchasing an additional 1,542 shares in the last quarter. Hedge funds and other institutional investors own 61.72% of the company’s stock.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.